View as cardsView as table

Developing a Biomarker of Homologous Recombination Deficiency for Enhanced PARP Inhibitor Efficacy Across Cancers

Fiscal Year Awarded:

2025

Principal Investigator:

Peter Park

Developing a novel screening platform to discover inflammasome modulating compounds

Fiscal Year Awarded:

2025

Principal Investigator:

Wade Harper

Developing a synthetic biology platform for pharmaceutical biomanufacturing

Fiscal Year Awarded:

2025

Principal Investigator:

Pamela Silver

Development of allosteric activators for immunotherapy

Fiscal Year Awarded:

2025

Principal Investigator:

Stephen Blacklow

Development of small molecule inhibitors of a gut bacterial metabolic toxin

Fiscal Year Awarded:

2025

Principal Investigator:

Sloan Devlin

In vivo gene editing to treat inherited Collagen VI-related myopathies

Fiscal Year Awarded:

2025

Principal Investigator:

Amy Wagers

In vivo strategy to induce tolerance to therapeutic proteins and autoantigens

Fiscal Year Awarded:

2025

Principal Investigator:

Amy Wagers

Investigating the mode of action of a highly selective insecticide and suitability for Anopheles management

Fiscal Year Awarded:

2025

Principal Investigator:

Norbert Perrimon

Oral pan-coronavirus anti-viral

Fiscal Year Awarded:

2025

Principal Investigator:

Timothy Mitchison

Structure-based discovery of chromatin remodeling inhibitors

Fiscal Year Awarded:

2025

Principal Investigator:

Lucas Farnung